TY - T1的安全性和有效性Tenecteplase和溶栓的串联病变患者中风:EXTEND-IA秋明石油公司的因果分析试验JF -神经学乔-神经- 10.1212 / WNL。半岛投注体育官网0000000000207138 SP - 10.1212 / WNL。0000000000207138 AU - Yogendrakumar Vignan AU - Churilov,狮子座流星群盟-米切尔,彼得·J AU - Kleinig Timothy J盟——Yassi Nawaf AU - Thijs,文森特•吴盟——泰迪AU -沙阿,有德盟-贝利,彼得AU -杜威,海伦米非盟-崔,菲利普MC AU - Ma,爱丽丝盟——韦杰Tissa盟——Garcia-Esperon卡洛斯盟——云,杰弗里盟——钱德拉Ronil诉AU - Cordato,丹尼斯·约翰盟——燕DMedSc伯纳德盟,沙玛,选手Gagan AU -德斯蒙德,帕特里夏·M AU -帕森斯马克·W AU -唐南杰弗里·艾伦AU -戴维斯,Stephen M AU -坎贝尔,布鲁斯·c·诉Y1 - 2023/03/06 UR - //www.ebmtp.com/content/early/2023/03/06/WNL.0000000000207138.abstract N2 -背景和目的:的安全性和有效性tenecteplase串联病变患者中风是未知的。半岛投注体育官网我们进行了比较分析tenecteplase和串联病变患者溶栓。方法:我们首先比较tenecteplase的治疗效果和患者的溶栓串联使用个别患者病变EXTEND-IA秋明石油公司的数据试验。我们在初始评估颅内再灌注血管造影评估和90天的夫人序数物流和弗斯回归模型。因为两个关键结果,死亡率和症状性颅内出血,很少在收到那些溶栓EXTEND-IA秋明石油公司试验,我们生成的混合估计这些结果通过补充试验数据估计入射通过荟萃分析研究确定在系统回顾。然后计算未经调整的风险差异比较集中发病率估计对于那些接受溶栓试验中观察到的那些接收tenecteplase。结果:483名患者(15%)的七十一年EXTEND-IA秋明石油公司试验具有串联病变。病变患者,观察颅内再灌注在11/56(20%)的tenecteplase治疗患者与1/15(7%)患者溶栓治疗(优势比:2.19;95%置信区间:0.28—-17.29)。观察无显著差异在90天的夫人(常见或调整:1.48; 95% CI: 0.44-5.00). A pooled study-level proportion of alteplase associated mortality and symptomatic intracranial hemorrhage was 0.14 (95% CI: 0.08-0.21) and 0.09 (95% CI: 0.04-0.16), respectively. Compared to a mortality rate of 0.09 (95% CI: 0.03-0.20) and a symptomatic intracranial hemorrhage rate of 0.07 (95% CI: 0.02-0.17) in tenecteplase treated patients, no significant difference was observed.Conclusions: Functional outcomes, mortality, and symptomatic intracranial hemorrhage did not significantly differ between tenecteplase and alteplase treated tandem lesion patients.Classification of Evidence: This study provides Class III evidence that tenecteplase is associated with similar rates of intracranial reperfusion, functional outcome, mortality, and symptomatic intracranial hemorrhage compared with alteplase, in patients with acute stroke due to tandem lesions. However, the confidence intervals do not rule out clinically important differences. ER -